## Status and Prospects of Liver Cirrhosis Treatment by Us and Mesenchymal Cells

Tissue Engineering - Part B: Reviews

20, 206-210

DOI: 10.1089/ten.teb.2013.0527

Citation Report

#	Article	IF	Citations
1	Pathogenesis of liver cirrhosis. World Journal of Gastroenterology, 2014, 20, 7312.	3.3	409
2	Cell therapy to remove excess copper in Wilson's disease. Annals of the New York Academy of Sciences, 2014, 1315, 70-80.	3.8	32
3	Enhanced survival of mice infused with bone marrow-derived as compared with adipose-derived mesenchymal stem cells. Hepatology Research, 2015, 45, 1353-1359.	3.4	24
4	Characterization and Comparison of Canine Multipotent Stromal Cells Derived from Liver and Bone Marrow. Stem Cells and Development, 2016, 25, 139-150.	2.1	18
5	Mesenchymal Stem Cells with Enhanced Bcl-2 Expression Promote Liver Recovery in a Rat Model of Hepatic Cirrhosis. Cellular Physiology and Biochemistry, 2016, 40, 1117-1128.	1.6	27
6	The current state of liver regeneration therapy. Acta Hepatologica Japonica, 2016, 57, 269-279.	0.1	O
7	Cell transplantation as a non-invasive strategy for treating liver fibrosis. Expert Review of Gastroenterology and Hepatology, 2016, 10, 639-648.	3.0	9
8	MiRâ€122 modification enhances the therapeutic efficacy of adipose tissueâ€derived mesenchymal stem cells against liver fibrosis. Journal of Cellular and Molecular Medicine, 2017, 21, 2963-2973.	3.6	155
9	Cell Therapy for Liver Disease Using Bioimaging Rats. Cell Medicine, 2017, 9, 3-7.	5.0	4
10	Effects of human umbilical cord blood mononuclear cells on respiratory system mechanics in a murine model of neonatal lung injury. Experimental Lung Research, 2017, 43, 66-81.	1.2	13
11	Copper-induced liver fibrosis affects the behavior of bone marrow cells in primary culture. Frontiers in Biology, 2017, 12, 271-279.	0.7	8
12	Molecular and functional characterization of CD133 + stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells. Cytotherapy, 2017, 19, 1447-1461.	0.7	7
13	Human Muse Cells, Nontumorigenic Phiripotent-Like Stem Cells, Have Liver Regeneration Capacity through Specific Homing and Cell Replacement in a Mouse Model of Liver Fibrosis. Cell Transplantation, 2017, 26, 821-840.	2.5	69
14	Current Understanding of Stem Cell and Secretome Therapies in Liver Diseases. Tissue Engineering and Regenerative Medicine, 2017, 14, 653-665.	3.7	10
15	Status of and candidates for cell therapy in liver cirrhosis: overcoming the "point of no return―in advanced liver cirrhosis. Journal of Gastroenterology, 2017, 52, 129-140.	5.1	58
16	BMSCs protect against liver injury via suppressing hepatocyte apoptosis and activating TGF- $\hat{l}^2$ 1/Bax singling pathway. Biomedicine and Pharmacotherapy, 2017, 96, 1395-1402.	5.6	18
17	Tissue Bioengineering in Transplantation. , 2017, , 181-213.		0
18	Tissue Engineering and Regenerative Medicine Solutions forÂthe Abdominal Organs. , 2017, , 325-347.		1

#	Article	IF	CITATIONS
19	Current Perspectives Regarding Stem Cell-Based Therapy for Liver Cirrhosis. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-19.	1.9	51
20	New Perspectives in Liver Transplantation: From Regeneration to Bioengineering. Bioengineering, 2019, 6, 81.	3.5	19
21	Advantages of adipose tissue stem cells over CD34+ mobilization to decrease hepatic fibrosis in Wistar rats. Annals of Hepatology, 2019, 18, 620-626.	1.5	12
22	Liver Macrophages: Old Dogmas and New Insights. Hepatology Communications, 2019, 3, 730-743.	4.3	256
23	The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future. Clinical and Molecular Hepatology, 2021, 27, 70-80.	8.9	67
24	Clinical and morphological case of developing liver cirrhosis associated with viral hepatitis in a young patient. Russian Journal of Infection and Immunity, 2021, 11, 784-788.	0.7	0
25	Effect of Autologous Bone Marrow Stem Cell Therapy in Patients with Liver Cirrhosis: A Meta-analysis. Journal of Clinical and Translational Hepatology, 2019, 7, 1-11.	1.4	17
26	Bone marrow-derived mesenchymal stem cell therapy for decompensated liver cirrhosis: A meta-analysis. World Journal of Gastroenterology, 2014, 20, 14051.	3.3	42
27	Mesenchymal stem cell therapy for cirrhosis: Present and future perspectives. World Journal of Gastroenterology, 2015, 21, 10253.	3.3	47
29	Impact of total splenectomy on peripheral lymphocytes and their subsets in patients with hypersplenism associated with cirrhotic portal hypertension. Scientific Reports, 2021, 11, 21246.	3.3	6
30	The effectiveness of autologous mesenchymal stem cells in the treatment of liver cirrhosis and the method of their visualization in the patient's body. Vestnik of Russian Military Medical Academy, 2020, 22, 35-40.	0.3	0
31	ECM1 modified HF-MSCs targeting HSC attenuate liver cirrhosis by inhibiting the TGF- $\hat{l}^2$ /Smad signaling pathway. Cell Death Discovery, 2022, 8, 51.	4.7	15
32	Mesenchymal stem cells in fibrotic diseasesâ€"the two sides of the same coin. Acta Pharmacologica Sinica, 2023, 44, 268-287.	6.1	19
33	Potential advantages of genetically modified mesenchymal stem cells in the treatment of acute and chronic liver diseases. Stem Cell Research and Therapy, 2023, $14$ , .	5 <b>.</b> 5	1